Skip to search formSkip to main contentSkip to account menu

SU014813

An orally-active, tyrosine kinase receptor inhibitor with potential antitumor activity. SU014813 binds to and inhibits the phosphorylation of… 
National Institutes of Health

Related topics

Related topics

8 relations
FLT1 protein, humanFLT3 protein, humanMast/Stem Cell Growth Factor Receptor Kit, humanPlatelet-Derived Growth Factor Receptor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
422 Antitumor Activity of BAL27862 (active Moiety of the Prodrug BAL101553) is Associated with the Generation of Short Non-centrosomal Microtubules
2009
2009
Untersuchung der möglichen Rolle von zirkulierenden vaskulären und lymphatischen Endothelzellen, sowie zirkulierenden Tumorzellen im Blut als Surrogatmarker für die klinische Wirkung bei der…
2008
2008
Phase I safety and pharmacokinetic (PK) study of SU014813 (S) in combination with docetaxel (D) in patients (pts) with solid tumors (STs)
3554 Background: S is an oral, multitargeted tyrosine kinase inhibitor (TKI) of PDGFRs, VEGFR-1 and -2, KIT and FLT3. This phase… 
2007
2007
Phase I trial of SU014813 in patients (pts) with advanced solid malignancies
3521 Background: SU014813 is an oral multi-targeted small molecule RTK inhibitor of VEGFRs, PDGFRs, sKIT & FLT-3 at nM… 
2005
2005
SU014813 is a novel multireceptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Receptor tyrosine kinases (RTK), such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)